These data suggest that dupilumab’s drug survival rate at 12 and 24 months is greater than that of upadacitinib and tralokinumab among patients with atopic dermatitis.

Use of obinutuzumab was associated with significant improvements in complete renal response rate and markers of disease activity in active lupus nephritis.

Panelists discuss how the BOREAS and NOTUS phase 3 trials demonstrated that dupilumab significantly reduced exacerbations, improved lung function, and enhanced quality of life in patients with uncontrolled chronic obstructive pulmonary disease (COPD), particularly those with elevated eosinophil counts, highlighting its potential in targeted therapy.

Panelists discuss how ensifentrine is a nebulized inhaled therapy, a small molecule inhibitor of PDE3 and PDE4, and is compelling because there are very few adverse effects. There are also compelling results from studies that show bronchial dilatation and exacerbation reduction.

ADP101 raised food allergy thresholds in children but missed its primary endpoint. Findings support further research into multi-food oral immunotherapy.

GLP-1 RA use was linked to a reduced risk of alcohol-associated liver disease, lower rates of hepatic decompensation, and improved survival.

Stanza previously demonstrated efficacy in helping to manage fibromyalgia in adult patients when compared with digital symptom tracking in phase 3 data.

SGLT2 inhibitors lower the risk of MACE in older age, despite smaller HbA1c reductions, while GLP-1 RAs were more cardioprotective in younger individuals with T2D.

In this analysis, investigators concluded that dupilumab may be a viable treatment choice for pregnant or breastfeeding mothers with atopic dermatitis.

New ACP migraine guidelines recommend β-blockers, valproate, venlafaxine, or amitriptyline for episodic migraine prevention before using CGRP-targeting drugs.

Findings highlight the need for early frailty screening in dialysis patients and the implementation of appropriate interventions to improve outcomes.

Brensocatib, also a potential first-in-class DPP1 inhibitor, has a PDUFA date of August 12, 2025.

The January 2025 ophthalmology month in review highlights the latest from the FDA, key updates to the ophthalmic pipeline, and the latest episode of New Insight.

Data from the phase 1 trial are intended to support dosing in a planned phase 2 trial in kidney transplant recipients.

This segment of Hebert’s interview features a discussion regarding the safety profile of tapinarof 1% for patients aged 2 years and older with atopic dermatitis.

January 2025 allergy research highlights dupilumab for CRSwNP, probiotics for food allergies, and links between parental age, environmental factors, and allergy risks.

Findings suggest the value of genotyping and histological assessment for guiding HCC screening decisions in patients with chronic HBV.

Despite being aware of its value in treating asthma, specialists were uncertain about integrating ITT into patient care.

Golimumab, marketed under the names Simponi and Simponi Aria, is approved for RA, PsA, AS, and UC.

Both doses of DURAVYU extended the time to the first supplemental injection versus aflibercept control in the Phase 2 VERONA trial.

These data point to milestone event frequency and prevalence by subtype of RDEB, highlighting such events as dysphagia and squamous cell carcinoma.

Drs. Levine and Sisti discuss the ethical challenges of GLP-1 drug allocation, exploring fairness, disparities, and policy solutions for obesity and diabetes treatment.

Adelaide Hebert, MD, discusses the impact of the recent approval for tapinarof cream in the management of atopic dermatitis.

Findings from the LIVERHOPE trial suggest adding simvastatin and rifaximin to standard therapy does not reduce ACLF occurrence.